|
|
 Previous Article | Table of Contents | Next Article 
Effect of Disease Stage on Clinical Outcome After Syngeneic Bone
Marrow Transplantation for Relapsing Experimental Autoimmune
Encephalomyelitis
Richard K. Burt,
Josette Padilla,
Wendy Smith Begolka,
Mauro C. Dal Canto, and
Stephen D. Miller
From the Department of Medicine, Department of
Microbiology-Immunology, Interdepartmental Immunobiology Center, and
Department of Pathology, Northwestern University Medical
School, Chicago, IL.
Relapsing experimental autoimmune encephalomyelitis (R-EAE) is an
immune-mediated demyelinating central nervous system (CNS) disease.
Myeloablation and syngeneic bone marrow transplantation (SBMT), when
performed at the peak of acute disease (day 14), prevented glial
scarring and ameliorated the disease severity. In contrast, when
syngeneic BMT was performed late in chronic phase (day 78), significant
glial scarring remained and the clinical severity did not differ
significantly from that of the controls. After SBMT in either the acute
or chronic phase of disease, the posttransplant immune system remained
responsive to myelin epitopes as determined by in vitro proliferation
and interferon- (IFN-) production. However, in mice undergoing
SBMT, in vivo delayed-type hypersensitivity (DTH) responses were
significantly decreased while IFN- RNA levels and inflammatory
infiltrates within the CNS were slightly improved. We conclude that
failure of SBMT to improve the clinical disease when performed in
chronic phase may be due to preexisting glial scarring. We also
conclude that in the absence of glial scarring and irreversible
neuronal injury, in vivo DTH responses and histology are better
predictors of clinical improvement than in vitro proliferation or
IFN- cytokine production.
Blood, Vol. 91 No. 7 (April 1), 1998:
pp. 2609-2616
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H Tsukamoto, K Nagafuji, T Horiuchi, T Miyamoto, K Aoki, K Takase, H Henzan, D Himeji, T Koyama, K Miyake, et al.
A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease
Ann Rheum Dis,
April 1, 2006;
65(4):
508 - 514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Burt
Finding a less toxic stem cell therapy for multiple sclerosis
Blood,
September 1, 2005;
106(5):
1514 - 1515.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Herrmann, S. Gaertner, C. Stadelmann, J. van den Brandt, R. Boscke, W. Budach, H. M. Reichardt, and R. Weissert
Tolerance induction by bone marrow transplantation in a multiple sclerosis model
Blood,
September 1, 2005;
106(5):
1875 - 1883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Burt, B. Cohen, J. Rose, F. Petersen, Y. Oyama, D. Stefoski, G. Katsamakis, E. Carrier, T. Kozak, P. A. Muraro, et al.
Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Arch Neurol,
June 1, 2005;
62(6):
860 - 864.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. van Bekkum
Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases
J. Leukoc. Biol.,
October 1, 2002;
72(4):
609 - 620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Burt, S. Slavin, W. H. Burns, and A. M. Marmont
Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?
Blood,
February 1, 2002;
99(3):
768 - 784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K Burt
Hematopoietic Stem Cell Therapy for Multiple Sclerosis
Multiple Sclerosis,
December 1, 2000;
6(6):
415 - 418.
[PDF]
|
|
|
|
|
|
|
T. Kushida, M. Inaba, K. Takeuchi, K. Sugiura, R. Ogawa, and S. Ikehara
Treatment of intractable autoimmune diseases in MRL/lpr mice using a new strategy for allogeneic bone marrow transplantation
Blood,
March 1, 2000;
95(5):
1862 - 1868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Burt, J. Padilla, M. C. Dal Canto, and S. D. Miller
Viral Hyperinfection of the Central Nervous System and High Mortality After Hematopoietic Stem Cell Transplantation for Treatment of Theiler's Murine Encephalomyelitis Virus-Induced Demyelinating Disease
Blood,
October 15, 1999;
94(8):
2915 - 2922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Burt, A. E. Traynor, R. Pope, J. Schroeder, B. Cohen, K. H. Karlin, L. Lobeck, C. Goolsby, P. Rowlings, F. A. Davis, et al.
Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation
Blood,
November 15, 1998;
92(10):
3505 - 3514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
